MediciNova, Inc. (MNOV) — Stock Valuation & Research

MediciNova, Inc. is a biopharmaceutical firm dedicated to discovering and advancing innovative small molecule therapies for severe illnesses where current treatments are insufficient within the United States. Its robust development pipeline features MN-166 (ibudilast), an oral agent with both anti-inflammatory and neuroprotective properties, currently being investigated for a range of neurological conditions. These include primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy,…

MNOV key statistics

Explore MNOV's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.